Pla2G6 Associated Neurodegeneration (Plan) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PLA2G6-associated neurodegeneration (PLAN) is a group of rare autosomal recessive neurodegenerative disorders caused by mutations in the PLA2G6 gene (Phospholipase A2, Group VI).[1] This condition encompasses a spectrum of phenotypes ranging from severe infantile-onset disease to adult-onset dystonia-parkinsonism.[2] [1]
PLA2G6 encodes calcium-independent phospholipase A2 (iPLA2-VI), an enzyme crucial for phospholipid metabolism and mitochondrial function in neurons.[3] Loss of iPLA2-VI activity leads to impaired membrane remodeling, mitochondrial dysfunction, and progressive neuronal death. [2]
The three main phenotypes within the PLAN spectrum include: [3]
| Property | Value | [4]
|----------|-------| [^6]
| Gene Symbol | PLA2G6 | [^7]
| Chromosomal Location | 22q12.1-q13.2 | [^8]
| Protein | Calcium-independent phospholipase A2 (iPLA2-VI) |
| Inheritance | Autosomal Recessive |
| OMIM | 603604 |
Over 100 pathogenic variants have been identified in PLA2G6, including missense, nonsense, splice-site, and frameshift mutations.[1] Common founder mutations have been described in various populations.[8]
The iPLA2-VI enzyme catalyzes the hydrolysis of the sn-2 position of phospholipids, releasing fatty acids including arachidonic acid, a precursor for pro-inflammatory eicosanoids.[3] Loss of enzymatic function leads to:
INAD presents in the first 2 years of life with:[4]
Typical disease course shows rapid progression with loss of ambulation within 2-3 years of onset. Most individuals do not survive beyond adolescence.
aNAD presents between ages 2-10 years with:[2]
Disease progression is slower than INAD, with survival into adulthood possible.
ADP presents in adolescence or adulthood with:[5]
This form has a more indolent course compared to the childhood-onset forms.
Diagnostic criteria include:
MRI findings in PLAN:[6]
Elevated neurofilament light chain (NfL) in cerebrospinal fluid has been reported as a biomarker of disease progression.
There is currently no disease-modifying therapy for PLAN. Treatment is supportive and symptomatic:
Research directions include:[7]
| Phenotype | Typical Course | Life Expectancy |
|---|---|---|
| INAD | Rapid progression | Death in childhood/adolescence |
| aNAD | Intermediate progression | Survival to adulthood |
| ADP | Slow progression | Normal or near-normal lifespan |
Mouse models with PLA2G6 knockout show:
These models are being used to test experimental therapeutics.[7]
Current research focuses on:
The study of Pla2G6 Associated Neurodegeneration (Plan) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
A female case of phospholipase A2 group VI-associated neurodegeneration with childhood onset and long-term follow-up until 49 years of age. ↩︎
Claval Hypertrophy with Persistent Diffusion Restriction in PLA2G6-Associated Neurodegeneration. ↩︎
A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series. ↩︎
Clinicoradiologic Features and Genetic Findings of Infantile Neuroaxonal Dystrophy. ↩︎